Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 1
1994 1
1995 5
1997 13
1998 8
1999 2
2000 6
2001 4
2002 18
2003 6
2004 6
2005 8
2006 1
2007 9
2008 10
2009 6
2010 10
2011 9
2012 5
2013 8
2014 5
2015 3
2016 4
2017 9
2018 8
2019 12
2020 21
2021 13
2022 8
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Results by year

Filters applied: . Clear all
Page 1
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter D, Yip S, Zhang AY, Zielinski RR, Davis ID; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Sweeney CJ, et al. Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3. Lancet Oncol. 2023. PMID: 36990608 Clinical Trial.
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Hussain M, et al. N Engl J Med. 2020 Dec 10;383(24):2345-2357. doi: 10.1056/NEJMoa2022485. Epub 2020 Sep 20. N Engl J Med. 2020. PMID: 32955174 Free article. Clinical Trial.
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Davis ID, et al. N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157964 Clinical Trial.
Reply by Authors.
Xu L, Mao X, Grey A, Scandura G, Guo T, Burke E, Marzec J, Abdu S, Stankiewicz E, Davies CR, Rajan P, Tipples K, Hines J, Chan PY, Campbell D, Wilkinson K, Kudahetti S, Shamash J, Oliver T, Berney D, Shaw G, Lu YJ. Xu L, et al. Among authors: shamash j. J Urol. 2020 Jan;203(1):81-82. doi: 10.1097/01.JU.0000602796.11621.76. Epub 2019 Oct 3. J Urol. 2020. PMID: 31580196 No abstract available.
Treatment de-escalation for stage II seminoma.
Wood GE, Chamberlain F, Tran B, Conduit C, Liow E, Nicol DL, Shamash J, Alifrangis C, Rajan P. Wood GE, et al. Among authors: shamash j. Nat Rev Urol. 2023 Aug;20(8):502-512. doi: 10.1038/s41585-023-00727-0. Epub 2023 Mar 7. Nat Rev Urol. 2023. PMID: 36882564 Review.
Germ-cell tumors.
Shamash J, Stebbing J, Powles T. Shamash J, et al. N Engl J Med. 2007 Oct 25;357(17):1771-2; author reply 1773-4. doi: 10.1056/NEJMc072495. N Engl J Med. 2007. PMID: 17960020 No abstract available.
197 results